China Medical System Holdings Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: HKG:867
China Medical System Holdings Ltd is active in the healthcare segment. It is one of the China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil, Salofalk, Combizym, Ganfule Capsules, Xidakang, Hirudoid, and others.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 231 out of 850
Universe
Global Universe 7983 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| China Medical System Holdings Ltd. |
25.6
Medium
|
231 out of 850 |
| The United Laboratories International Holdings Ltd. |
27.8
Medium
|
374 out of 850 |
| Hypera SA |
33.4
High
|
636 out of 850 |
| IDEAYA Biosciences, Inc. |
33.7
High
|
646 out of 850 |
| China Meheco Group Co., Ltd. |
40.5
Severe
|
826 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
How do the ESG Risk Ratings work?
Top Material ESG Issues for China Medical System Holdings Ltd.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted China Medical System Holdings Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level
Contributing Events
Highest Controversy Events Locations
